18862478098_0b3e1a0999_k
News
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...
BridgeBio’s BEYONTTRA approved by European Commission to treat ATTR-CM
The European Commission has granted marketing authorization in the European Union (EU) for BridgeBio Pharma's acoramidis, under the brand name BEYONTTRA, for the treatment...
UK unveils funding for AI companies to transform cancer care and spark new drug...
New AI models to diagnose and treat cancer and other incurable diseases will be made possible thanks to joint public-private investment giving flexible funding...
